+Follow
嗣舒
No personal profile
20
Follow
0
Followers
0
Topic
0
Badge
Posts
Hot
嗣舒
2024-10-12
Share your opinion about this news…
Sorry, the original content has been removed
嗣舒
2024-05-22
Share your opinion about this news…
The "upgraded version" of semaglutide is here! Eli Lilly Tilpotide Injection Approved in China
Go to Tiger App to see more news
{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4115205500438802","uuid":"4115205500438802","gmtCreate":1652106048121,"gmtModify":1697841292118,"name":"嗣舒","pinyin":"sssishu","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":20,"tweetSize":2,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":2,"symbols":null,"coverImage":null,"realNameVerified":"init","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.02.03","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"President Tiger","description":"The transaction amount of the securities account reaches $1,000,000","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.05.25","exceedPercentage":"93.71%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.11","exceedPercentage":"93.75%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.06.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.31","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.02.03","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},"individualDisplayBadges":null,"crmLevel":13,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":9,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":359181164835000,"gmtCreate":1728698717312,"gmtModify":1728698869527,"author":{"id":"4115205500438802","authorId":"4115205500438802","name":"嗣舒","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4115205500438802","idStr":"4115205500438802"},"themes":[],"htmlText":"Share your opinion about this news…","listText":"Share your opinion about this news…","text":"Share your opinion about this news…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/359181164835000","repostId":"2474093237","repostType":2,"isVote":1,"tweetType":1,"viewCount":207,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":308452813885640,"gmtCreate":1716327705420,"gmtModify":1716329540126,"author":{"id":"4115205500438802","authorId":"4115205500438802","name":"嗣舒","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4115205500438802","idStr":"4115205500438802"},"themes":[],"htmlText":"Share your opinion about this news…","listText":"Share your opinion about this news…","text":"Share your opinion about this news…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/308452813885640","repostId":"2437446249","repostType":2,"repost":{"id":"2437446249","kind":"news","pubTimestamp":1716276750,"share":"https://ttm.financial/m/news/2437446249?lang=en_US&edition=fundamental","pubTime":"2024-05-21 15:32","market":"us","language":"zh","title":"The \"upgraded version\" of semaglutide is here! Eli Lilly Tilpotide Injection Approved in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2437446249","media":"华尔街见闻","summary":"替尔泊肽比司美格鲁肽减肥效果更好，当GIP与GLP-1受体激动剂联合使用时，可能会对患者血糖和体重产生更大的影响。","content":"<p><html><head></head><body><strong>Tilpotide is more effective than semaglutide for weight loss, and when GIP is used in combination with a GLP-1 receptor agonist, it may have a greater effect on patient blood glucose and weight.</strong></p><p>The competition on the weight loss pill track is becoming increasingly fierce,<a href=\"https://laohu8.com/S/LLY\">Eli Lilly</a>Mu Fengda was approved for listing in China.</p><p>On May 21, the official website of the State Food and Drug Administration showed<strong>, Eli Lilly Mufengda (Tilpotide Injection) was approved by the National Medical Products Administration (NMPA) to improve blood sugar control in adult patients with type 2 diabetes.</strong></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/77c56e4948bd5b7d48cfb79e511e5054\" tg-width=\"716\" tg-height=\"211\"/></p><p>Tilpotide is a GIPR and GLP-1R agonist that is injected once a week. GLP-1 and GIP are two natural enterotropins. Studies have shown that GIP can reduce food intake, increase energy expenditure, and thus reduce weight.<strong>When GIP is used in combination with GLP-1 receptor agonists, it may have a greater impact on patient blood glucose and body weight.</strong></p><p><strong>It is worth mentioning that telpotide can produce a better weight loss effect than semaglutide, which is known as the \"magic medicine for weight loss\".</strong></p><p>Relevant research data showed that the average weight loss of Mufengda 5mg and 10mg subjects was 7.8 kg and 10.3 kg, and the average weight loss of semaglutide 1mg group was 6.2 kg.</p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1cd6a793f8dc35a0cc9d5e0520c59d39\" tg-width=\"756\" tg-height=\"372\"/></p><p>Last year, telpotide was approved by the FDA for chronic weight management, as well as weight-related comorbidities such as hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea or cardiovascular disease, under the trade name Zepbound.<strong>At present, the application for marketing of telpotide for weight loss indications has also been accepted by the Food and Drug Administration and is under review.</strong></p><p>In addition, the sales of diet pills are also significantly boosting Eli Lilly's performance. Zepbound's sales in the first quarter of its listing exceeded expectations, contributing US $517 million in sales in the full quarter, exceeding analysts' expectations of US $418 million. The company also raised its full-year revenue guidance by $2 billion.</p><p>Industry analysts previously predicted that telpotide may become one of the best-selling drugs in history, with annual sales exceeding 50 billion US dollars, which will exceed<a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>Of semaglutide drugs Ozempic and Wegovy.</p><p>Eli Lilly's current market value is $744.3 billion, higher than that of S&P constituent stocks<a href=\"https://laohu8.com/S/TSLA\">Tesla</a>、<a href=\"https://laohu8.com/S/WMT\">Walmart</a>, is the pharmaceutical company with the highest market value in the world.</p><p></body></html></p>","source":"wallstreetcn_hot_news","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The \"upgraded version\" of semaglutide is here! Eli Lilly Tilpotide Injection Approved in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe \"upgraded version\" of semaglutide is here! Eli Lilly Tilpotide Injection Approved in China\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">华尔街见闻</strong><span class=\"h-time small\">2024-05-21 15:32</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><head></head><body><strong>Tilpotide is more effective than semaglutide for weight loss, and when GIP is used in combination with a GLP-1 receptor agonist, it may have a greater effect on patient blood glucose and weight.</strong></p><p>The competition on the weight loss pill track is becoming increasingly fierce,<a href=\"https://laohu8.com/S/LLY\">Eli Lilly</a>Mu Fengda was approved for listing in China.</p><p>On May 21, the official website of the State Food and Drug Administration showed<strong>, Eli Lilly Mufengda (Tilpotide Injection) was approved by the National Medical Products Administration (NMPA) to improve blood sugar control in adult patients with type 2 diabetes.</strong></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/77c56e4948bd5b7d48cfb79e511e5054\" tg-width=\"716\" tg-height=\"211\"/></p><p>Tilpotide is a GIPR and GLP-1R agonist that is injected once a week. GLP-1 and GIP are two natural enterotropins. Studies have shown that GIP can reduce food intake, increase energy expenditure, and thus reduce weight.<strong>When GIP is used in combination with GLP-1 receptor agonists, it may have a greater impact on patient blood glucose and body weight.</strong></p><p><strong>It is worth mentioning that telpotide can produce a better weight loss effect than semaglutide, which is known as the \"magic medicine for weight loss\".</strong></p><p>Relevant research data showed that the average weight loss of Mufengda 5mg and 10mg subjects was 7.8 kg and 10.3 kg, and the average weight loss of semaglutide 1mg group was 6.2 kg.</p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1cd6a793f8dc35a0cc9d5e0520c59d39\" tg-width=\"756\" tg-height=\"372\"/></p><p>Last year, telpotide was approved by the FDA for chronic weight management, as well as weight-related comorbidities such as hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea or cardiovascular disease, under the trade name Zepbound.<strong>At present, the application for marketing of telpotide for weight loss indications has also been accepted by the Food and Drug Administration and is under review.</strong></p><p>In addition, the sales of diet pills are also significantly boosting Eli Lilly's performance. Zepbound's sales in the first quarter of its listing exceeded expectations, contributing US $517 million in sales in the full quarter, exceeding analysts' expectations of US $418 million. The company also raised its full-year revenue guidance by $2 billion.</p><p>Industry analysts previously predicted that telpotide may become one of the best-selling drugs in history, with annual sales exceeding 50 billion US dollars, which will exceed<a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>Of semaglutide drugs Ozempic and Wegovy.</p><p>Eli Lilly's current market value is $744.3 billion, higher than that of S&P constituent stocks<a href=\"https://laohu8.com/S/TSLA\">Tesla</a>、<a href=\"https://laohu8.com/S/WMT\">Walmart</a>, is the pharmaceutical company with the highest market value in the world.</p><p></body></html></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"https://wallstreetcn.com/articles/3715379\">华尔街见闻</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/83f07867b8f6f3f3fcb868d0fc0fa6be","relate_stocks":{"LLY":"礼来"},"source_url":"https://wallstreetcn.com/articles/3715379","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2437446249","content_text":"替尔泊肽比司美格鲁肽减肥效果更好，当GIP与GLP-1受体激动剂联合使用时，可能会对患者血糖和体重产生更大的影响。减肥药赛道竞争愈发激烈，礼来穆峰达在华获批上市。5月21日，国家药监局官网显示，礼来穆峰达（替尔泊肽注射液）获得国家药品监督管理局（NMPA）批准，用以改善成人2型糖尿病患者的血糖控制。替尔泊肽是一款每周注射一次的GIPR和GLP-1R激动剂。GLP-1和GIP是两种天然的肠促胰素，研究表明GIP可以减少食物摄入、增加能量消耗，从而减轻体重。当GIP与GLP-1受体激动剂联合使用时，可能会对患者血糖和体重产生更大的影响。值得一提的是，替尔泊肽能产生比有”减肥神药”之称的司美格鲁肽更好的减肥效果。相关研究数据表明表明，穆峰达5mg、10mg受试者体重平均降低7.8 kg、10.3 kg，司美格鲁肽1mg组平均降低6.2kg。去年，替尔泊肽获FDA批准用于慢性体重管理，以及体重相关合并症，如高血压、血脂异常、2型糖尿病、阻塞性睡眠呼吸暂停或心血管疾病，商品名为Zepbound。目前替尔泊肽减重适应症上市申请也获药监局受理，正在审评中。此外，减肥药大卖也在显著推升礼来业绩，Zepbound上市首季销售额超预期，完整季度就贡献5.17亿美元销售额，超出分析师预期的4.18亿美元。公司同时将全年营收指引上调20亿美元。此前有行业分析师预测，替尔泊肽可能成为有史以来最畅销的药物之一，年销售额将突破500亿美元，将超过诺和诺德的司美格鲁肽药物Ozempic和Wegovy。目前礼来市值达7443亿美元，高于标普成分股中的特斯拉、沃尔玛，为全球市值最高的药企。","news_type":1,"symbols_score_info":{"LLY":1}},"isVote":1,"tweetType":1,"viewCount":212,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":359181164835000,"gmtCreate":1728698717312,"gmtModify":1728698869527,"author":{"id":"4115205500438802","authorId":"4115205500438802","name":"嗣舒","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4115205500438802","idStr":"4115205500438802"},"themes":[],"htmlText":"Share your opinion about this news…","listText":"Share your opinion about this news…","text":"Share your opinion about this news…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/359181164835000","repostId":"2474093237","repostType":2,"isVote":1,"tweetType":1,"viewCount":207,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":308452813885640,"gmtCreate":1716327705420,"gmtModify":1716329540126,"author":{"id":"4115205500438802","authorId":"4115205500438802","name":"嗣舒","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4115205500438802","idStr":"4115205500438802"},"themes":[],"htmlText":"Share your opinion about this news…","listText":"Share your opinion about this news…","text":"Share your opinion about this news…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/308452813885640","repostId":"2437446249","repostType":2,"repost":{"id":"2437446249","kind":"news","pubTimestamp":1716276750,"share":"https://ttm.financial/m/news/2437446249?lang=en_US&edition=fundamental","pubTime":"2024-05-21 15:32","market":"us","language":"zh","title":"The \"upgraded version\" of semaglutide is here! Eli Lilly Tilpotide Injection Approved in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2437446249","media":"华尔街见闻","summary":"替尔泊肽比司美格鲁肽减肥效果更好，当GIP与GLP-1受体激动剂联合使用时，可能会对患者血糖和体重产生更大的影响。","content":"<p><html><head></head><body><strong>Tilpotide is more effective than semaglutide for weight loss, and when GIP is used in combination with a GLP-1 receptor agonist, it may have a greater effect on patient blood glucose and weight.</strong></p><p>The competition on the weight loss pill track is becoming increasingly fierce,<a href=\"https://laohu8.com/S/LLY\">Eli Lilly</a>Mu Fengda was approved for listing in China.</p><p>On May 21, the official website of the State Food and Drug Administration showed<strong>, Eli Lilly Mufengda (Tilpotide Injection) was approved by the National Medical Products Administration (NMPA) to improve blood sugar control in adult patients with type 2 diabetes.</strong></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/77c56e4948bd5b7d48cfb79e511e5054\" tg-width=\"716\" tg-height=\"211\"/></p><p>Tilpotide is a GIPR and GLP-1R agonist that is injected once a week. GLP-1 and GIP are two natural enterotropins. Studies have shown that GIP can reduce food intake, increase energy expenditure, and thus reduce weight.<strong>When GIP is used in combination with GLP-1 receptor agonists, it may have a greater impact on patient blood glucose and body weight.</strong></p><p><strong>It is worth mentioning that telpotide can produce a better weight loss effect than semaglutide, which is known as the \"magic medicine for weight loss\".</strong></p><p>Relevant research data showed that the average weight loss of Mufengda 5mg and 10mg subjects was 7.8 kg and 10.3 kg, and the average weight loss of semaglutide 1mg group was 6.2 kg.</p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1cd6a793f8dc35a0cc9d5e0520c59d39\" tg-width=\"756\" tg-height=\"372\"/></p><p>Last year, telpotide was approved by the FDA for chronic weight management, as well as weight-related comorbidities such as hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea or cardiovascular disease, under the trade name Zepbound.<strong>At present, the application for marketing of telpotide for weight loss indications has also been accepted by the Food and Drug Administration and is under review.</strong></p><p>In addition, the sales of diet pills are also significantly boosting Eli Lilly's performance. Zepbound's sales in the first quarter of its listing exceeded expectations, contributing US $517 million in sales in the full quarter, exceeding analysts' expectations of US $418 million. The company also raised its full-year revenue guidance by $2 billion.</p><p>Industry analysts previously predicted that telpotide may become one of the best-selling drugs in history, with annual sales exceeding 50 billion US dollars, which will exceed<a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>Of semaglutide drugs Ozempic and Wegovy.</p><p>Eli Lilly's current market value is $744.3 billion, higher than that of S&P constituent stocks<a href=\"https://laohu8.com/S/TSLA\">Tesla</a>、<a href=\"https://laohu8.com/S/WMT\">Walmart</a>, is the pharmaceutical company with the highest market value in the world.</p><p></body></html></p>","source":"wallstreetcn_hot_news","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The \"upgraded version\" of semaglutide is here! Eli Lilly Tilpotide Injection Approved in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe \"upgraded version\" of semaglutide is here! Eli Lilly Tilpotide Injection Approved in China\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">华尔街见闻</strong><span class=\"h-time small\">2024-05-21 15:32</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><head></head><body><strong>Tilpotide is more effective than semaglutide for weight loss, and when GIP is used in combination with a GLP-1 receptor agonist, it may have a greater effect on patient blood glucose and weight.</strong></p><p>The competition on the weight loss pill track is becoming increasingly fierce,<a href=\"https://laohu8.com/S/LLY\">Eli Lilly</a>Mu Fengda was approved for listing in China.</p><p>On May 21, the official website of the State Food and Drug Administration showed<strong>, Eli Lilly Mufengda (Tilpotide Injection) was approved by the National Medical Products Administration (NMPA) to improve blood sugar control in adult patients with type 2 diabetes.</strong></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/77c56e4948bd5b7d48cfb79e511e5054\" tg-width=\"716\" tg-height=\"211\"/></p><p>Tilpotide is a GIPR and GLP-1R agonist that is injected once a week. GLP-1 and GIP are two natural enterotropins. Studies have shown that GIP can reduce food intake, increase energy expenditure, and thus reduce weight.<strong>When GIP is used in combination with GLP-1 receptor agonists, it may have a greater impact on patient blood glucose and body weight.</strong></p><p><strong>It is worth mentioning that telpotide can produce a better weight loss effect than semaglutide, which is known as the \"magic medicine for weight loss\".</strong></p><p>Relevant research data showed that the average weight loss of Mufengda 5mg and 10mg subjects was 7.8 kg and 10.3 kg, and the average weight loss of semaglutide 1mg group was 6.2 kg.</p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1cd6a793f8dc35a0cc9d5e0520c59d39\" tg-width=\"756\" tg-height=\"372\"/></p><p>Last year, telpotide was approved by the FDA for chronic weight management, as well as weight-related comorbidities such as hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea or cardiovascular disease, under the trade name Zepbound.<strong>At present, the application for marketing of telpotide for weight loss indications has also been accepted by the Food and Drug Administration and is under review.</strong></p><p>In addition, the sales of diet pills are also significantly boosting Eli Lilly's performance. Zepbound's sales in the first quarter of its listing exceeded expectations, contributing US $517 million in sales in the full quarter, exceeding analysts' expectations of US $418 million. The company also raised its full-year revenue guidance by $2 billion.</p><p>Industry analysts previously predicted that telpotide may become one of the best-selling drugs in history, with annual sales exceeding 50 billion US dollars, which will exceed<a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>Of semaglutide drugs Ozempic and Wegovy.</p><p>Eli Lilly's current market value is $744.3 billion, higher than that of S&P constituent stocks<a href=\"https://laohu8.com/S/TSLA\">Tesla</a>、<a href=\"https://laohu8.com/S/WMT\">Walmart</a>, is the pharmaceutical company with the highest market value in the world.</p><p></body></html></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"https://wallstreetcn.com/articles/3715379\">华尔街见闻</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/83f07867b8f6f3f3fcb868d0fc0fa6be","relate_stocks":{"LLY":"礼来"},"source_url":"https://wallstreetcn.com/articles/3715379","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2437446249","content_text":"替尔泊肽比司美格鲁肽减肥效果更好，当GIP与GLP-1受体激动剂联合使用时，可能会对患者血糖和体重产生更大的影响。减肥药赛道竞争愈发激烈，礼来穆峰达在华获批上市。5月21日，国家药监局官网显示，礼来穆峰达（替尔泊肽注射液）获得国家药品监督管理局（NMPA）批准，用以改善成人2型糖尿病患者的血糖控制。替尔泊肽是一款每周注射一次的GIPR和GLP-1R激动剂。GLP-1和GIP是两种天然的肠促胰素，研究表明GIP可以减少食物摄入、增加能量消耗，从而减轻体重。当GIP与GLP-1受体激动剂联合使用时，可能会对患者血糖和体重产生更大的影响。值得一提的是，替尔泊肽能产生比有”减肥神药”之称的司美格鲁肽更好的减肥效果。相关研究数据表明表明，穆峰达5mg、10mg受试者体重平均降低7.8 kg、10.3 kg，司美格鲁肽1mg组平均降低6.2kg。去年，替尔泊肽获FDA批准用于慢性体重管理，以及体重相关合并症，如高血压、血脂异常、2型糖尿病、阻塞性睡眠呼吸暂停或心血管疾病，商品名为Zepbound。目前替尔泊肽减重适应症上市申请也获药监局受理，正在审评中。此外，减肥药大卖也在显著推升礼来业绩，Zepbound上市首季销售额超预期，完整季度就贡献5.17亿美元销售额，超出分析师预期的4.18亿美元。公司同时将全年营收指引上调20亿美元。此前有行业分析师预测，替尔泊肽可能成为有史以来最畅销的药物之一，年销售额将突破500亿美元，将超过诺和诺德的司美格鲁肽药物Ozempic和Wegovy。目前礼来市值达7443亿美元，高于标普成分股中的特斯拉、沃尔玛，为全球市值最高的药企。","news_type":1,"symbols_score_info":{"LLY":1}},"isVote":1,"tweetType":1,"viewCount":212,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}
